Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada
Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...
Hosted on MSN2d
Celltrion's asthma treatment greenlit for Canadian release
Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...
Yonhap News English on MSN2d
Celltrion wins approval for allergic asthma treatment biosimilar in Canada
South Korea's pharmaceutical giant Celltrion Inc. said Monday that it has received approval from Canadian health authorities ...
Celltrion secures Canada's approval for Xolair biosimilar Omlyclo
South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...
kedglobal2d
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...